 | | Vol. 14.38 – 6 October, 2023 |
| |
|
|
| Using neuroendocrine prostate cancer-related genome sequencing database analyses, scientists screened RacGTP enzyme activating protein 1 (RACGAP1), a common differentially expressed gene. They investigated RACGAP1 expression in clinical prostate cancer specimens by IHC.
[Aging and Disease] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers developed a combinatorial nanomedicine comprising abiraterone and enzalutamide bioconjugated survivin-encapsulated gold nanoparticles for targeted therapy of prostate cancer.
[European Journal of Pharmaceutics and Biopharmaceutics] |
|
|
|
| Investigators confirmed that pinostilbene directly bound to androgen receptor and inhibited its activation and translocalization. Their results suggested that pinostilbene has the potential to treat enzalutamide-resistant CRPC.
[Scientific Reports] |
|
|
|
| Scientists suggested that editing of miR-379 attenuated the growth-suppressive function of unedited miR-379 in androgen-sensitive prostate cancer cells, thereby promoting tumor growth.
[Scientific Reports] |
|
|
|
| Researchers explored Lupeol’s potential in enhancing the chemosensitivity of chemoresistant prostate cancer cells to enzalutamide in vitro and in a mouse model.
[Toxicology and Applied Pharmacology] |
|
|
|
| In vitro CRPC cell lines were used to determine the effect of YAP1 on glutamine uptake and metabolism to glutathione and RSL3-induced ferroptosis.
[Molecular And Cellular Biochemistry] |
|
|
|
| In vitro/ex vivo analysis of erdafitinib and CH5183284 demonstrated robust and moderate growth suppression of androgen receptor-positive CRPC, respectively.
[The Prostate] |
|
|
|
| Employing taxane-resistant DU145-TXR cells and a combination of cytotoxicity, apoptosis, and cell cycle assays, scientists’ findings demonstrated that fatty acid binding protein 5 knockdown sensitized the cells to docetaxel.
[PLOS One] |
|
|
|
| The authors found that cannabidiol decreased prostate cancer cell viability up to 37.25% and induced apoptotic cell death in a time and dose-dependent manner.
[PLOS One] |
|
|
|
|
| In prostate cancer, the exosome is the regulator of cancer progression. Scientists highlight the exosome theranostics signature in prostate cancer and its association with male fertility.
[Drug Discovery Today] |
|
|
|
|
|
South Korea’s scientists have been left reeling after the government proposed substantial cuts to the 2024 federal research budget. Government spending on research and development in the country has been among the highest in the world and the announcement has sparked a rare outcry from researchers.
[Nature] |
| |
|
|
| October 23 – 25, 2023
Toronto, Ontario, Canada |
|
|
|
|
|
| | Stanford University – Stanford, California, United States |
|
|
|
| | Fred Hutchinson Cancer Center – Seattle, Washington, United States |
|
|
|
| | Cedars-Sinai – Los Angeles, California, United States |
|
|
|
| | Massachusetts General Hospital – Boston, Massachusetts, United States |
|
|
|
| | Cancer Research UK Manchester Institute – Manchester, England, United Kingdom |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
